Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

744
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
744
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

597
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
597
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

2.7K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.7K
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

415
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
415
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

2.7K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
2.7K
Asthma-IV: Nursing Management01:30

Asthma-IV: Nursing Management

3.3K
The nursing management of asthma is a comprehensive approach that relies heavily on the expertise and dedication of healthcare professionals. It involves thorough assessment, accurate diagnosis, strategic planning, effective implementation, and diligent evaluation. By meticulously following this step-by-step process, healthcare professionals play a crucial role in providing the best possible care and treatment for patients with asthma, enhancing their overall health and well-being.
First, in...
3.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multiplex Cytokine LTT Reveals Strong T Cell Responses to Multiple Drugs in NIDHR-Associated Multiple Drug Hypersensitivity.

The journal of allergy and clinical immunology. In practice·2026
Same author

Update of the evidence- and consensus-based S3 guideline on atopic dermatitis: Systemic therapy with biologics or Janus kinase inhibitors and specific aspects of systemic therapy in pregnancy and lactation.

Allergologie select·2026
Same author

Dupilumab improves symptoms and quality of life in patients with eosinophilic esophagitis: a plain language summary.

Immunotherapy·2026
Same author

Molecular Characterization of Non-Specific Esophagitis Reveals a Distinct Non-Eosinophilic Phenotype With Fibrotic Traits.

Allergy·2026
Same author

Sleep positional therapy for patients with systemic sclerosis and nighttime gastroesophageal reflux symptoms.

Rheumatology international·2026
Same author

Body Weight Changes After Peroral Endoscopic Myotomy: Overweight Achalasia Patients.

Neurogastroenterology and motility·2026

Related Experiment Video

Updated: Sep 25, 2025

Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis
03:23

Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis

Published on: May 10, 2024

947

Improving Care in Eosinophil-Associated Diseases: A Charter.

David J Jackson1,2, Praveen Akuthota3, Rebeca Andradas4

  • 1Guy's Severe Asthma Centre, Guy's Hospital, Guy's and St Thomas' NHS Trust, School of Immunology and Microbial Sciences, King's College London, London, SE1 9RT, UK. David.Jackson@gstt.nhs.uk.

Advances in Therapy
|April 30, 2022
PubMed
Summary

Eosinophil-associated diseases (EADs) require improved recognition and timely diagnosis for better patient outcomes. This charter outlines patient rights and an action plan for enhanced EAD care and treatment accessibility.

Keywords:
Eosinophil-associated diseasesEosinophilic immune dysfunction (EID)Healthcare professional (HCP) educationMultidisciplinary teams (MDTs)Patient educationPatient rightsTimely diagnosis

More Related Videos

Methodology for Sputum Induction and Laboratory Processing
13:28

Methodology for Sputum Induction and Laboratory Processing

Published on: December 17, 2017

27.9K
Conditional Reprogramming of Pediatric Human Esophageal Epithelial Cells for Use in Tissue Engineering and Disease Investigation
10:15

Conditional Reprogramming of Pediatric Human Esophageal Epithelial Cells for Use in Tissue Engineering and Disease Investigation

Published on: March 22, 2017

7.1K

Related Experiment Videos

Last Updated: Sep 25, 2025

Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis
03:23

Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis

Published on: May 10, 2024

947
Methodology for Sputum Induction and Laboratory Processing
13:28

Methodology for Sputum Induction and Laboratory Processing

Published on: December 17, 2017

27.9K
Conditional Reprogramming of Pediatric Human Esophageal Epithelial Cells for Use in Tissue Engineering and Disease Investigation
10:15

Conditional Reprogramming of Pediatric Human Esophageal Epithelial Cells for Use in Tissue Engineering and Disease Investigation

Published on: March 22, 2017

7.1K

Area of Science:

  • Immunology
  • Pathology
  • Clinical Medicine

Background:

  • Eosinophil-associated diseases (EADs) encompass diverse conditions where eosinophils play a key pathological role.
  • Common EADs include eosinophilic asthma and chronic rhinosinusitis; rarer forms include hypereosinophilic syndromes (HES) and eosinophilic gastrointestinal disorders (EGIDs).
  • EADs impose significant patient burdens, including chronic symptoms, financial strain, reduced quality of life, and frequent healthcare interactions.

Purpose of the Study:

  • To establish key patient rights and expectations for managing EADs.
  • To propose an action plan for improving health outcomes in patients with EADs.

Main Methods:

  • The study outlines a charter detailing principles for quality EAD care.
  • Key recommendations include increased awareness, timely diagnosis, multidisciplinary team access, and prompt access to treatments.

Main Results:

  • The charter emphasizes four core principles for EAD management: greater awareness and education, timely and accurate diagnosis, access to multidisciplinary teams, and access to safe, effective treatments without delay.
  • Adoption of these principles is expected to reduce patient and caregiver burden and improve outcomes.

Conclusions:

  • Healthcare professionals, systems, and policymakers are urged to adopt the charter's principles.
  • Swift adoption will ensure timely diagnosis and access to high-level care for EAD patients.